Rybelsus (Being Discontinued in the US) vs Zepbound: Tablet vs Strongest Shot
Rybelsus (semaglutide (oral), Novo Nordisk) vs Zepbound (tirzepatide, Eli Lilly)
Last verified October 2026
The verdict
A daily diabetes tablet against a weekly obesity injection, and the numbers reflect the mismatch: −3.7 kg at 26 weeks on Rybelsus 14 mg in PIONEER 1 against −20.9% at 72 weeks in SURMOUNT-1. Rybelsus is not approved for weight management, and in the US it is being discontinued in favor of Ozempic tablets ($149–$299 a month self-pay). Zepbound costs $299–$449 a month through LillyDirect. If a pill is the requirement rather than a preference, Foundayo and the Wegovy tablet, both approved for weight, are the more relevant comparisons.
Side-by-side comparison
| Field | Rybelsus | Zepbound |
|---|---|---|
| How you take it | A tablet daily, on an empty stomach, then 30 minutes of nothing else | An injection under the skin, once a week |
| How it works | Semaglutide, a GLP-1 receptor agonist, paired with an absorption enhancer so a fraction survives the stomach | Tirzepatide, which hits two receptors, GIP and GLP-1, rather than one |
| Weight lost in the pivotal trial | -3.7 kg, about -4%, over 26 weeks at 14 mg (PIONEER 1) | -20.9% over 72 weeks at 15 mg (SURMOUNT-1) |
| What it is approved to treat | Type 2 diabetes since 2019, including lowering heart risk; not weight | Long-term weight management since 2023; obstructive sleep apnea since December 2024 |
| Blood-sugar reduction | -0.9% to -1.4% over 26 weeks at 14 mg on its own (PIONEER 1) | Not labeled for diabetes. The same molecule under its diabetes brand reached -2.30% in SURPASS-2 |
| Whether food gets in the way | Strictly: empty stomach, no more than 4 oz of plain water, and nothing to eat, drink or swallow for 30 minutes | None at all — inject whenever, with or without food |
| What a higher-dose pill could do | The Wegovy tablet (oral semaglutide 25 mg, approved for weight) reached -13.6% over 64 weeks in OASIS 4. Rybelsus stops at 14 mg | -20.9% over 72 weeks at 15 mg, already approved and on the shelf |
| What it costs if you pay cash | $149–$299/mo self-pay as Ozempic tablets, its US replacement | $299 to $449/mo through LillyDirect Self Pay (KwikPen or vial) |
What each one costs in the compounded market
Standing monthly cash prices from the 734 sellers on this register. These are compounded preparations, not the approved products compared above.
Rybelsus — semaglutide (oral)
from $47 /mo
463 sellers publish a standing price. This is the lowest of all 463; the median is $174 a month.
Where to get semaglutide — a selection of sellers, not a price ranking
- Embody review$79/mo
- SnagRx review$99/mo
- Collective review$59/mo + membership
Zepbound — tirzepatide
from $69 /mo
453 sellers publish a standing price. This is the lowest of all 453; the median is $228.28 a month.
Where to get tirzepatide — a selection of sellers, not a price ranking
- Embody review$129/mo
- SnagRx review$149/mo
- Collective review$69/mo + membership
⚠ A compounded preparation is not the approved product. No agency has reviewed that specific preparation for safety, effectiveness or manufacturing quality, and the legal ground under compounding these molecules narrowed when the shortages closed. The price gap is real, and so is the difference in oversight. Every seller, with its price record.
Frequently asked questions
Are Rybelsus and Zepbound the same drug?
No. Rybelsus is semaglutide (oral) and Zepbound is tirzepatide — different molecules. Results with one do not predict results with the other.
Is Rybelsus or Zepbound cheaper?
On the manufacturers' own cash pricing: Rybelsus at $149–$299/mo self-pay as Ozempic tablets, its US replacement, Zepbound at $299 to $449/mo through LillyDirect Self Pay (KwikPen or vial). That is the list-price comparison, and it is not what most people pay. What you actually pay depends on whether your plan covers it, which formulary tier it sits in, and whether you have met your deductible — and for many people the honest comparison is between an insured copay and a cash-pay compounded alternative rather than between these two figures.
What does a compounded version of each actually cost?
Across the 734 sellers in this register, the cheapest standing monthly cash prices we hold are semaglutide (oral) from $47 a month and tirzepatide from $69 a month. A compounded preparation is not the approved product: no agency has reviewed that specific preparation for safety, effectiveness or manufacturing quality, and the legal ground under compounding these molecules narrowed once the shortages closed. The price gap is real and so is the difference in oversight.
Can I switch from Rybelsus to Zepbound?
Yes, with a prescriber. Expect to re-titrate from the bottom of the new drug's ladder rather than starting where you left off: these are different molecules and tolerance to one does not transfer to the other. Both the old drug's washout and the new drug's schedule apply.
Which one should I ask for?
That is a prescriber's call, and anyone answering it from a table is guessing. What a page like this can do is tell you what the trials measured, what the manufacturers charge, and where the evidence is still missing, so the conversation starts from the record rather than from an advertisement.
References
- 1.Aroda VR, Rosenstock J, Terauchi Y, et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. 2019. PMID: 31186300.
- 2.Knop FK, Aroda VR, do Vale RD, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023. PMID: 37385278.
- 3.Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. PMID: 35658024.
- 4.Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA). N Engl J Med. 2024. PMID: 38912654.
- 5.Novo Nordisk. RYBELSUS and OZEMPIC (semaglutide) tablets — Prescribing Information (revised January 2026). DailyMed (NIH/NLM). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98
- 6.Eli Lilly and Company. ZEPBOUND (tirzepatide) injection — FDA Prescribing Information. DailyMed (NIH/NLM). 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
- 7.Wharton S, Lingvay I, Bogdanski P, et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity (OASIS 4). N Engl J Med. 2025. PMID: 40934115.
- 8.Novo Nordisk. Ozempic (semaglutide) pill available in the US starting May 4 (press release, May 1, 2026). Novo Nordisk US newsroom. 2026. https://www.novonordisk-us.com/media/news-archive/news-details.html?id=916540
Related comparisons
- Rybelsus vs Mounjaro
- Mounjaro vs Zepbound
- Zepbound vs Contrave
- Zepbound vs Qsymia
- Wegovy vs Rybelsus
- Zepbound vs Trulicity
See the full drug-vs-drug verdict index or provider rankings.